The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Eisai
Consulting or Advisory Role - Genentech; Lilly; Nektar; Novartis; Puma Biotechnology; Seagen
Research Funding - G1 Therapeutics; Lilly; Merck; Merrimack; Nektar; Novartis; Puma Biotechnology; Seagen; Tesaro
Patents, Royalties, Other Intellectual Property - Jones and Bartlett; UpToDate
A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC).
 
Carey K. Anders
No Relationships to Disclose
 
Emilie Le Rhun
Honoraria - Mundipharma; Novartis
Consulting or Advisory Role - Abbvie; Daiichi Sankyo
Research Funding - Amgen (Inst); Mundipharma (Inst)
 
Thomas Denis Bachelot
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Novartis; pfizer; Roche
 
Denise A. Yardley
Consulting or Advisory Role - Biotheranostics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo/Lilly (Inst); Eisai (Inst); Genentech/Roche (Inst); NanoString Technologies (Inst); Novartis (Inst)
Speakers' Bureau - Genentech/Roche; Genentech/Roche; Novartis
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Immunomedics (Inst); InventisBio (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Syndax (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Novartis
 
Ahmad Awada
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Ipsen; Leo Pharma; Lilly; Novartis; NS Pharma; Pfizer; Roche
Travel, Accommodations, Expenses - Ipsen; Pfizer; Roche
 
Pier Franco Conte
Speakers' Bureau - AstraZeneca; Novartis; Roche/Genentech
Research Funding - Merck Serono (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis
 
Peter Kabos
Consulting or Advisory Role - Lilly
Research Funding - Radius Health (Inst)
 
Melissa Bear
Employment - Indiana University Health; Lilly
Stock and Other Ownership Interests - Lilly
 
Zhengyu Yang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Yanyun Chen
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Sara M. Tolaney
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Celldex; Eisai; Genentech; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology; Sanofi; Tesaro
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celldex; Eisai; Genentech/Roche; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology